Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Longeveron Posts 32% Revenue Drop in Q2

TheMotleyFool

0 0

Longeveron Posts 32% Revenue Drop in Q2Photo, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Longeveron (NASDAQ:LGVN), a clinical-stage biotechnology firm focused on stem cell therapies for rare and aging-related diseases, released its second quarter earnings on August 13, 2025.

The most notable headline was a deepening net loss for the six months ended June 30, 2025, driven by increased clinical and manufacturing development expenses, while revenue exceeded analyst expectations and the cash runway tightened.

Longeveron reported a basic and diluted net loss per share of $0.33.

Source Fool.com

Like: 0

LGVN

Teilen